

## LEADING MICROBIOLOGY JOURNAL PUBLISHES APAS® CLINICAL DATA

*The Johns Hopkins APAS® Independence evaluation data published in the Journal of Clinical Microbiology*

**Adelaide, Australia, 18 August 2021:** Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the publication in the Journal of Clinical Microbiology (**JCM**), of the clinical results from the evaluation of the APAS® Independence by The Johns Hopkins Hospital.

### The Johns Hopkins MRSA Study and Results

In 2020, The Johns Hopkins Hospital and School of Medicine, Maryland, United States, conducted a clinical evaluation of the APAS® Independence to detect the presence of Methicillin-resistant *Staphylococcus aureus* or MRSA as part of their routine infection control surveillance program. The study assessed the ability of the APAS® Independence with the MRSA analysis module to identify culture plates for the presence of presumptive MRSA and compared the APAS® results with the laboratory's current manual plate reading practices. The study of 5,913 patient samples demonstrated both the accuracy of the APAS® Independence to identify presumptive MRSA as well as its ability to deliver efficiencies within a routine clinical setting. Key findings from the study included:

- No false negatives: APAS® Independence achieves 100% Positive Percent Agreement (95% Confidence Interval)
- APAS® Independence identified a further 5 positive MRSA samples, previously missed by the microbiologists

Interim results were originally released as an ePoster at the ASM's 2020 conference ASM Microbe Online (*Comparison of an Automated Plate Assessment System (APAS® Independence) and Artificial Intelligence (AI) to Manual Plate Reading of Methicillin-resistant Staphylococcus aureus Chromagar Surveillance Cultures*) with the updated and full results now presented in the JCM publication.

The full study results are available via the JCM website and will be published on the LBT website once freely available. To access the article on the JCM website please use the following link: <https://journals.asm.org/doi/10.1128/JCM.00971-21>

LBT Scientific Director, Steven Giglio said:

*"We are proud to have this study published in such a prestigious, high impact journal, and especially when authored by The Johns Hopkins Hospital and School of Medicine, which is an institution that acts as a source of reference for scientific excellence and thought leadership around the world. This is a true testament to the quality of the work and the impact the APAS® Independence can have on our industry. Along with the 5 posters presented recently at the ECCMID conference there is a growing body of evidence to support broader awareness and adoption of artificial intelligence solutions such as the APAS® Independence."*

### Journal of Clinical Microbiology

The JCM is a peer reviewed medical journal published by the American Society for Microbiology (**ASM**), the oldest and largest single life science membership organisation in the world. With over 30,000 members, JCM is a high impact publication that represents 26% of all microbiology articles and contributes 44% of all microbiology citations. JCM is regarded as the premier journal for clinical microbiology diagnostics, and each publication requires a thorough and vigorous assessment of the data by a panel of experts in the field, with only those papers that demonstrate significant novelty and clinical application being chosen for publication.

Approved for release by the Chair of the LBT Board.

**About LBT Innovations**

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. Beckman Coulter have also been appointed as Marketing Agent in Europe to assist in facilitating sales. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

**CONTACTS**

<b>LBT Innovations</b>	<b>Investor Enquiries</b>
<b>Brent Barnes</b> Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>	<b>David Allen / John Granger</b> Hawkesbury Partners Tel: +61 2 9103 9494 E: <a href="mailto:jgranger@hawkesburypartners.com">jgranger@hawkesburypartners.com</a>